European Call for the future Next Generation Sequencing (NGS) solutions for cancer
Increasing the use of Next Generation Sequencing (NGS) in oncology requires further cost reduction and technology acceleration. 8 health procurers from 5 countries (BE, FR, DE, ES, IT) invite potentially interested bidders to submit an offer for their oncNGS pre-commercial procurement.
Aim of the procurement is to develop an affordable integrated solution for predictive, prognostic and diagnostic analysis in liquid biopsies of solid tumours based on NGS technology. Deadline for submission of offers: extended to 17 October 2022.
- Bidders can participate in a joint tender and look for suitable partners through the oncNGS matchmaking page.
- A Frequently Asked Questions page is also available on the oncNGS website.